{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T07:03:58Z","timestamp":1784099038436,"version":"3.55.0"},"reference-count":97,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The management of locally advanced rectal cancer (LARC) has progressively shifted beyond surgery alone toward integrated protocols that include neoadjuvant chemoradiotherapy (nCRT). Even so, the risks of distant metastasis and organ dysfunction remain significant challenges. It is against this backdrop that immune checkpoint inhibitors (ICIs) combined with chemoradiotherapy have begun to redefine therapeutic possibilities. Radiotherapy (RT) induces immunogenic cell death (ICD), enhances antigen presentation, and activates systemic immune responses, whereas ICIs overcome immune suppression by blocking pathways such as PD-1\/PD-L1. This synergistic approach converts immunologically cold tumors into infiltrated, hot phenotypes. Building on this rationale, recent Phase II trials have explored immune consolidation following short-course radiotherapy (SCRT) within a total neoadjuvant therapy (TNT) framework. What emerged was particularly compelling: pathological complete response (pCR) rates rose notably, in some cases doubling historical benchmarks. This improvement is not merely a numerical gain; it translates into tangible clinical opportunities, including organ preservation and the feasibility of watch-and-wait (W&amp;amp;W) protocols for selected responders. Notably, SCRT appears especially compatible with subsequent immunotherapy, perhaps due to its abbreviated yet potent immunomodulatory effects, offering a pragmatic alternative to conventional long-course regimens. Looking ahead, the push toward personalization is gaining momentum. Biomarkers like MMR\/MSI status, features of the tumor immune microenvironment, and dynamic changes in ctDNA are increasingly guiding trial design and treatment sequencing. While promising, these tools require further validation in larger, more diverse cohorts. Ultimately, the central question remains: how can we convert higher pCR rates into lasting survival benefits while safeguarding quality of life? Answering this will depend on rigorously designed Phase III trials, thoughtful integration of predictive biomarkers, and continued refinement of how and when we combine radiation, chemotherapy, and immunotherapy. Only then can we ensure that advances in biology translate into meaningful human outcomes.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1832333","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:05:35Z","timestamp":1784095535000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Synergistic neoadjuvant radioimmunotherapy in locally advanced rectal cancer: mechanisms of pathologic response and the shift toward organ preservation"],"prefix":"10.3389","volume":"17","author":[{"given":"Shu","family":"Yan","sequence":"first","affiliation":[{"name":"Department of Tumor Radiotherapy, Jilin City Hospital of Chemical Industry","place":["Jilin, China"]},{"name":"Department of Tumor Radiotherapy, The Second Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangchao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Tumor Radiotherapy, Jilin City Hospital of Chemical Industry","place":["Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Tumor Radiotherapy, The Second Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/jso.27531","article-title":"Evolution of therapy for locally advanced rectal cancer","volume":"129","author":"Altomare","year":"2024","journal-title":"J Surg Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30600","article-title":"Total neoadjuvant therapy for rectal cancer: An emerging option","volume":"123","author":"Ludmir","year":"2017","journal-title":"Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2022.911538","article-title":"Total neoadjuvant therapy (TNT) versus standard neoadjuvant chemoradiotherapy for locally advanced rectal cancer: A systematic review and meta-analysis","volume":"26","author":"Liu","year":"2021","journal-title":"Oncologist"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/dcr.0000000000000558","article-title":"Pathologic complete response in rectal cancer: Can we detect it? Lessons learned from a proposed randomized trial of watch-and-wait treatment of rectal cancer","volume":"59","author":"Nahas","year":"2016","journal-title":"Dis Colon Rectum"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-018-3006-x","article-title":"Outcome of bowel function following anterior resection for rectal cancer-an analysis using the low anterior resection syndrome (LARS) score","volume":"33","author":"Kupsch","year":"2018","journal-title":"Int J Colorectal Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/jso.28001","article-title":"Watch-and-wait approach following neoadjuvant chemo-radiotherapy for locally advanced rectal cancer: A retrospective single-center cohort study","volume":"131","author":"Kalev","year":"2025","journal-title":"J Surg Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(10)70172-8","article-title":"Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data","volume":"11","author":"Maas","year":"2010","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0071","article-title":"Adoption of total neoadjuvant therapy for locally advanced rectal cancer","volume":"4","author":"Cercek","year":"2018","journal-title":"JAMA Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(09)70381-x","article-title":"Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial","volume":"11","author":"Chua","year":"2010","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2014.07.021","article-title":"Neoadjuvant sandwich treatment with oxaliplatin and capecitabine administered prior to, concurrently with, and following radiation therapy in locally advanced rectal cancer: a prospective phase 2 trial","volume":"90","author":"Gao","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03360-5","article-title":"Neoadjuvant chemoradiation with or without PD-1 blockade in locally advanced rectal cancer: a randomized phase 2 trial","volume":"31","author":"Yang","year":"2025","journal-title":"Nat Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.02261","article-title":"Randomized phase II trial of immunotherapy-based total neoadjuvant therapy for proficient mismatch repair or microsatellite stable locally advanced rectal cancer (TORCH)","volume":"42","author":"Xia","year":"2024","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znaf057","article-title":"Impact of PD1 blockade added to neoadjuvant chemoradiotherapy on rectal cancer surgery: post-hoc analysis of the randomized POLARSTAR trial","volume":"112","author":"Pang","year":"2025","journal-title":"Br J Surg"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4149\/neo_2021_201210n1341","article-title":"Assessment of the expression and response of PD-1, LAG-3, and TIM-3 after neoadjuvant radiotherapy in rectal cancer","volume":"68","author":"Peng","year":"2021","journal-title":"Neoplasma"},{"key":"B16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.trecan.2021.10.003","article-title":"Radiotherapy and immunotherapy: open questions and future strategies","volume":"8","author":"Pointer","year":"2022","journal-title":"Trends Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20180139","article-title":"The cGAS\u2013cGAMP\u2013STING pathway connects DNA damage to inflammation, senescence, and cancer","volume":"215","author":"Li","year":"2018","journal-title":"J Exp Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.10.019","article-title":"STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors","volume":"41","author":"Deng","year":"2014","journal-title":"Immunity"},{"key":"B19","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/s41419-023-05999-3","article-title":"New insights into the responder\/nonresponder divide in rectal cancer: Damage-induced type I IFNs dictate treatment efficacy and can be targeted to enhance radiotherapy","volume":"14","author":"Uccello","year":"2023","journal-title":"Cell Death Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat Commun"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-23-1078","article-title":"The exonuclease TREX1 constitutes an innate immune checkpoint limiting cGAS\/STING-mediated antitumor immunity","volume":"12","author":"Lim","year":"2024","journal-title":"Cancer Immunol Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.705361","article-title":"Immunogenic cell death induction by ionizing radiation","volume":"12","author":"Zhu","year":"2021","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.5694\/mja2.12046","article-title":"Radiotherapy and immunotherapy: a synergistic effect in cancer care","volume":"210","author":"Turgeon","year":"2019","journal-title":"Med J Aust"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.12.7516","article-title":"Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor","volume":"174","author":"Lugade","year":"2005","journal-title":"J Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.5.3099","article-title":"Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells","volume":"181","author":"Matsumura","year":"2008","journal-title":"J Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1693277","article-title":"A metabolic-radioimmune signature predicts therapy response and immune reprogramming in non-small cell lung cancer","volume":"15","author":"Zhu","year":"2025","journal-title":"Front Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-25-0454","article-title":"CD8+ T cell antitumor immunity via human iNKT-DC conjugates","volume":"14","author":"Baiu","year":"2026","journal-title":"Cancer Immunol Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2024.12.079","article-title":"Co-activating STING-TLR9 pathways promotes radiotherapy-induced cancer vaccination","volume":"379","author":"Sun","year":"2025","journal-title":"J Ctrl Release"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1038\/s42003-025-08983-z","article-title":"Druggable genome CRISPR screening identifies the KEAP1\/NRF2 axis as a mediator of PD-L1 expression","volume":"8","author":"Seker-Polat","year":"2025","journal-title":"Commun Biol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.canlet.2013.09.018","article-title":"Abscopal effects of radiation therapy: a clinical review for the radiobiologist","volume":"356","author":"Siva","year":"2015","journal-title":"Cancer Lett"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.02.024","article-title":"PAI-1-driven SFRP2(high) cancer-associated fibroblasts hijack the abscopal effect of radioimmunotherapy","volume":"43","author":"Zhang","year":"2025","journal-title":"Cancer Cell"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2018.6","article-title":"Using immunotherapy to boost the abscopal effect","volume":"18","author":"Ngwa","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/adbi.202100758","article-title":"The PD-1 interactome","volume":"5","author":"Wang","year":"2021","journal-title":"Adv Biol (Weinh)"},{"key":"B34","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-013027","article-title":"Macrophage CCL7 promotes resistance to immunotherapy for colorectal cancer by regulating the infiltration of macrophages and CD8(+) T cells","volume":"13","author":"Chen","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-21-3213","article-title":"Preoperative chemoradiotherapy plus nivolumab before surgery in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer","volume":"28","author":"Bando","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13045-025-01734-x","article-title":"Immune checkpoint inhibitors for the treatment of solid tumors and lymphoma in the past 26 years (2000-2025)","volume":"18","author":"Huang","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1097\/js9.0000000000001960","article-title":"Efficacy and safety of combining short-course neoadjuvant chemoradiotherapy with envafolimab in locally advanced rectal cancer patients with microsatellite stability: a phase II PRECAM experimental study","volume":"111","author":"Wang","year":"2025","journal-title":"Int J Surg"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(25)00286-4","article-title":"Total neoadjuvant treatment with short-course radiotherapy followed by sintilimab plus capecitabine-oxaliplatin versus short-course radiotherapy followed by capecitabine-oxaliplatin in patients with locally advanced rectal cancer (SPRING-01): a single-centre, open-label, phase 2, randomised controlled trial","volume":"26","author":"Tian","year":"2025","journal-title":"Lancet Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s12885-022-09348-z","article-title":"Short-course radiotherapy combined with CAPOX and Toripalimab for the total neoadjuvant therapy of locally advanced rectal cancer: a randomized, prospective, multicentre, double-arm, phase II trial (TORCH)","volume":"22","author":"Wang","year":"2022","journal-title":"BMC Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn441530-20230107-00010","article-title":"Short-course radiotherapy combined with CAPOX and PD-1 inhibitor for the total neoadjuvant therapy of locally advanced rectal cancer: the preliminary single-center findings of a prospective, multicentre, randomized phase II trial (TORCH)","volume":"26","author":"Wang","year":"2023","journal-title":"Zhonghua Wei Chang Wai Ke Za Zhi"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.06.015","article-title":"Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): early outcomes of a multicenter randomized phase III trial","volume":"35","author":"Lin","year":"2024","journal-title":"Ann Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1200563","article-title":"Radiotherapy promotes tumor-specific effector CD8+ T cells via dendritic cell activation","volume":"189","author":"Gupta","year":"2012","journal-title":"J Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaoncol.2021.2301","article-title":"Pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non-small cell lung cancer: The phase 2 KEYNOTE-799 nonrandomized trial","volume":"7","author":"Jabbour","year":"2021","journal-title":"JAMA Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1200\/jco-25-00036","article-title":"Simultaneous durvalumab and platinum-based chemoradiotherapy in unresectable stage III non-small cell lung cancer: The phase III PACIFIC-2 study","volume":"43","author":"Bradley","year":"2025","journal-title":"J Clin Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0805-8","article-title":"Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers","volume":"26","author":"Chalabi","year":"2020","journal-title":"Nat Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)01808-7","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"404","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"B49","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.ijrobp.2018.06.404","article-title":"Kinetics of intratumoral immune cell activation during chemoradiation for cervical cancer","volume":"102","author":"Dorta-Estremera","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B50","doi-asserted-by":"publisher","first-page":"11909","DOI":"10.1038\/s41598-024-62871-w","article-title":"Fluorescence tracking demonstrates T cell recirculation is transiently impaired by radiation therapy to the tumor","volume":"14","author":"Kramer","year":"2024","journal-title":"Sci Rep"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2024.100906","article-title":"Neoadjuvant chemoradiotherapy up-regulates PD-L1 in radioresistant colorectal cancer","volume":"51","author":"Bae","year":"2025","journal-title":"Clin Trans Radiat Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1509051","article-title":"Effects of chemoradiotherapy on surface PD-L1 expression in esophageal cancer and its implications for immunotherapy","volume":"15","author":"Hampe","year":"2024","journal-title":"Front Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2021.39.15_suppl.3511","article-title":"Phase II study of preoperative (PREOP) chemoradiotherapy (CTRT) plus avelumab (AVE) in patients (PTS) with locally advanced rectal cancer (LARC): The AVANA study","volume":"39","author":"Salvatore","year":"2021","journal-title":"J Clin Oncol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"S432","DOI":"10.1016\/j.annonc.2023.09.1790","article-title":"599P R-IMMUNE: A phase Ib\/II study to evaluate safety and efficacy of atezolizumab combined with radio-chemotherapy in a preoperative setting for patients with locally advanced rectal cancer (LARC)","volume":"34","author":"Carrasco","year":"2023","journal-title":"Ann Oncol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"S537","DOI":"10.1016\/j.annonc.2021.08.919","article-title":"397P R-IMMUNE interim analysis: A phase Ib\/II study to evaluate safety and efficacy of atezolizumab combined with radio-chemotherapy in a preoperative setting for patients with localized rectal cancer","volume":"32","author":"Carrasco","year":"2021","journal-title":"Ann Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.1683","article-title":"Use of total neoadjuvant therapy for locally advanced rectal cancer","volume":"7","author":"Rahma","year":"2021","journal-title":"JAMA Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2023.41.4_suppl.7","article-title":"Long-term results from NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC)","volume":"41","author":"George","year":"2023","journal-title":"J Clin Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2020.38.15_suppl.4100","article-title":"Short-term results of VOLTAGE-A: Nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer","volume":"38","author":"Yuki","year":"2020","journal-title":"J Clin Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2023.41.4_suppl.108","article-title":"Survival outcomes and functional results of VOLTAGE-A: Preoperative chemoradiotherapy (CRT) and consolidation nivolumab (nivo) in patients (pts) with both microsatellite stable (MSS) and microsatellite instability\u2013high (MSI-H) locally advanced rectal cancer (LARC)","volume":"41","author":"Tsukada","year":"2023","journal-title":"J Clin Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2021.39.3_suppl.100","article-title":"Translational research of VOLTAGE-A: Efficacy predictors of preoperative chemoradiotherapy and consolidation nivolumab in patients with both microsatellite stable and microsatellite instability-high locally advanced rectal cancer","volume":"39","author":"Inamori","year":"2021","journal-title":"J Clin Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101824","article-title":"Phase II study of capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer: the PANDORA trial","volume":"8","author":"Grassi","year":"2023","journal-title":"ESMO Open"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2022.40.16_suppl.e15603","article-title":"The clinical efficacy and safety of neoadjuvant chemoradiation therapy with immunotherapy for the organ preservation of ultra low rectal cancer: A single arm and open label exploratory study","volume":"40","author":"Zhou","year":"2022","journal-title":"J Clin Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2022.40.16_suppl.3611","article-title":"Total neoadjuvant chemoradiation combined with neoadjuvant PD-1 blockade for patients with pMMR, high-risk, and locally advanced middle to low rectal cancer","volume":"40","author":"Wu","year":"2022","journal-title":"J Clin Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2023.7996","article-title":"Total neoadjuvant therapy with PD-1 blockade for high-risk proficient mismatch repair rectal cancer","volume":"159","author":"Li","year":"2024","journal-title":"JAMA Surg"},{"key":"B65","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/s1470-2045(20)30555-6","article-title":"Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial","volume":"22","author":"Bahadoer","year":"2021","journal-title":"Lancet Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1067036","article-title":"Neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced rectal cancer: A new era for anal preservation","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.103992","article-title":"Current status of locally advanced rectal cancer therapy and future prospects","volume":"186","author":"Koukourakis","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-09-0265","article-title":"Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody","volume":"15","author":"Dewan","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1111\/codi.17090","article-title":"Preoperative short\u2010course radiotherapy followed by chemotherapy and PD\u20101 inhibitor administration for locally advanced rectal cancer: A study protocol of a randomized phase II\/III trial (STELLAR II study)","volume":"26","author":"Zhang","year":"2024","journal-title":"Colorectal Dis"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2024.07.1025","article-title":"Preoperative short-course radiotherapy followed by chemotherapy and PD-1 inhibitor administration for locally advanced rectal cancer: the initial results of a randomized controlled clinical trial (STELLAR II)","volume":"47","author":"Li","year":"2025","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100807","article-title":"Short-course-based TNT with or without PD-1 inhibitor for pMMR locally advanced rectal cancer: Phase 2 results of a randomized trial (STELLAR II)","volume":"6","author":"Tang","year":"2025","journal-title":"Med"},{"key":"B72","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s12916-025-04087-x","article-title":"Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy for locally advanced rectal cancer: 3-year survival from a phase 2 study","volume":"23","author":"Lin","year":"2025","journal-title":"BMC Med"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-066976","article-title":"Combining chemotherapy and tislelizumab with preoperative split-course hypofraction radiotherapy for locally advanced rectal cancer: study protocol of a prospective, single-arm, phase II trial","volume":"13","author":"Zheng","year":"2023","journal-title":"BMJ Open"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1186\/s12885-024-12994-0","article-title":"Node-sparing modified short-course radiotherapy combined with CAPOX and tislelizumab for locally advanced MSS of middle and low rectal cancer (mRCAT): an open-label, single-arm, prospective, multicentre clinical trial","volume":"24","author":"Cai","year":"2024","journal-title":"BMC Cancer"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andre","year":"2020","journal-title":"N Engl J Med"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00197-8","article-title":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study","volume":"23","author":"Diaz","year":"2022","journal-title":"Lancet Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1182299","article-title":"Locally advanced rectal cancer with dMMR\/MSI-H may be excused from surgery after neoadjuvant anti-PD-1 monotherapy: a multiple-center, cohort study","volume":"14","author":"Yang","year":"2023","journal-title":"Front Immunol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.07.016","article-title":"Anti-PD-1-based immunotherapy as curative-intent treatment in dMMR\/MSI-H rectal cancer: A multicentre cohort study","volume":"174","author":"Wang","year":"2022","journal-title":"Eur J Cancer"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103929","article-title":"Curative immune checkpoint inhibitors therapy in patients with mismatch repair-deficient locally advanced rectal cancer: a real-world observational study","volume":"9","author":"Tosi","year":"2024","journal-title":"ESMO Open"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.913483","article-title":"Efficacy and safety of neoadjuvant monoimmunotherapy with PD-1 inhibitor for dMMR\/MSI rectangleH locally advanced colorectal cancer: A single-center real-world study","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/po.17.00189","article-title":"Microsatellite instability testing using next-generation sequencing data and therapy implications","volume":"1","author":"Haraldsdottir","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1392499","article-title":"The efficacy and safety of neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced rectal cancer patients: a systematic review","volume":"15","author":"Yang","year":"2024","journal-title":"Front Immunol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1097\/js9.0000000000002795","article-title":"Applicability of cCR assessment criteria in pMMR rectal cancer patients treated with neoadjuvant chemoradiotherapy combined with immunotherapy","volume":"111","author":"Pei","year":"2025","journal-title":"Int J Surg"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.01932","article-title":"Multicenter, randomized, phase III trial of neoadjuvant chemoradiation with capecitabine and irinotecan guided by UGT1A1 status in patients with locally advanced rectal cancer","volume":"38","author":"Zhu","year":"2020","journal-title":"J Clin Oncol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02877-z","article-title":"Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal\/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses","volume":"30","author":"Kelly","year":"2024","journal-title":"Nat Med"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003741","article-title":"Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: A prospective cohort study","volume":"18","author":"Wang","year":"2021","journal-title":"PloS Med"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2014.46","article-title":"Radiation enteropathy\u2014pathogenesis, treatment and prevention","volume":"11","author":"Hauer-Jensen","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviscsurg.2020.08.012","article-title":"Radiation enteritis: Diagnostic and therapeutic issues","volume":"157","author":"Loge","year":"2020","journal-title":"J Visceral Surg"},{"key":"B89","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s11894-014-0383-3","article-title":"Radiation enteritis","volume":"16","author":"Harb","year":"2014","journal-title":"Curr Gastroenterol Rep"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3857\/roj.2023.00346","article-title":"Research progress and treatment of radiation enteritis and gut microbiota","volume":"41","author":"Ren","year":"2023","journal-title":"Radiat Oncol J"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102440","article-title":"Immune checkpoint inhibitor\u2013induced diarrhea and colitis: incidence and management. A systematic review and meta-analysis","volume":"109","author":"Nielsen","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1097\/01.sla.0000141194.27992.32","article-title":"Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results","volume":"240","author":"Habr-Gama","year":"2004","journal-title":"Ann Surg"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)31078-x","article-title":"Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study","volume":"391","author":"van der Valk","year":"2018","journal-title":"Lancet"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1097\/ppo.0000000000000731","article-title":"The role of circulating tumor DNA for management of patients with rectal cancer: challenges and opportunities","volume":"30","author":"Sahin","year":"2024","journal-title":"Cancer J"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17152560","article-title":"Circulating tumor DNA detects minimal residual disease in patients with locally advanced rectal cancer after total neoadjuvant therapy","volume":"17","author":"Kim","year":"2025","journal-title":"Cancers"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlb.2025.100338","article-title":"Repositioning ctDNA as a real-time clinical compass: a meta-analysis of 14,000 patients across 42 studies","volume":"9","author":"Tharwat Kamouna","year":"2025","journal-title":"J Liquid Biopsy"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1832333\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:05:37Z","timestamp":1784095537000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1832333\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":97,"alternative-id":["10.3389\/fimmu.2026.1832333"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1832333","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"article-number":"1832333"}}